[Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease.
[Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.
New Positive allosteric modulators of nicotinic acetylcholine receptor
申请人:Eskildsen Jørgen
公开号:US20130012530A1
公开(公告)日:2013-01-10
The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.
SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER
申请人:Kowa Company, Ltd.
公开号:EP2281817A1
公开(公告)日:2011-02-09
It is to provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease.
It is a carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.